463 related articles for article (PubMed ID: 34201346)
1. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Waddell AR; Huang H; Liao D
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201346
[TBL] [Abstract][Full Text] [Related]
2. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer.
Waddell A; Mahmud I; Ding H; Huo Z; Liao D
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199844
[TBL] [Abstract][Full Text] [Related]
4. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation.
Fu M; Wang C; Reutens AT; Wang J; Angeletti RH; Siconolfi-Baez L; Ogryzko V; Avantaggiati ML; Pestell RG
J Biol Chem; 2000 Jul; 275(27):20853-60. PubMed ID: 10779504
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-4 activates androgen receptor through CBP/p300.
Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
[TBL] [Abstract][Full Text] [Related]
7. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
9. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J; Chen Z; Qiao Y; Tien JC; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
bioRxiv; 2024 May; ():. PubMed ID: 38586029
[TBL] [Abstract][Full Text] [Related]
10. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
11. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
Gou P; Zhang W
Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
[TBL] [Abstract][Full Text] [Related]
12. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
13. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
14. Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer.
Jaiswal B; Agarwal A; Gupta A
Front Endocrinol (Lausanne); 2022; 13():886594. PubMed ID: 36060957
[TBL] [Abstract][Full Text] [Related]
15. The transcriptional coactivators p300 and CBP are histone acetyltransferases.
Ogryzko VV; Schiltz RL; Russanova V; Howard BH; Nakatani Y
Cell; 1996 Nov; 87(5):953-9. PubMed ID: 8945521
[TBL] [Abstract][Full Text] [Related]
16. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
bioRxiv; 2024 May; ():. PubMed ID: 38766099
[TBL] [Abstract][Full Text] [Related]
17. Factor-specific modulation of CREB-binding protein acetyltransferase activity.
Perissi V; Dasen JS; Kurokawa R; Wang Z; Korzus E; Rose DW; Glass CK; Rosenfeld MG
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3652-7. PubMed ID: 10097092
[TBL] [Abstract][Full Text] [Related]
18. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles.
Chakraborty S; Senyuk V; Sitailo S; Chi Y; Nucifora G
J Biol Chem; 2001 Nov; 276(48):44936-43. PubMed ID: 11568182
[TBL] [Abstract][Full Text] [Related]
19. Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity.
Ray S; Sherman CT; Lu M; Brasier AR
Mol Endocrinol; 2002 Apr; 16(4):824-36. PubMed ID: 11923478
[TBL] [Abstract][Full Text] [Related]
20. p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
Fan S; Ma YX; Wang C; Yuan RQ; Meng Q; Wang JA; Erdos M; Goldberg ID; Webb P; Kushner PJ; Pestell RG; Rosen EM
Cancer Res; 2002 Jan; 62(1):141-51. PubMed ID: 11782371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
